Apriso is a medication used to treat ulcerative colitis [1]. It is available in a delayed-release capsule formulation [2].
What is the active ingredient in Apriso?
The active ingredient in Apriso is mesalamine, also known as 5-aminosalicylic acid (5-ASA) [1]. Mesalamine is an anti-inflammatory drug [3].
How does Apriso work for ulcerative colitis?
Apriso works by reducing inflammation in the colon [3]. The delayed-release capsules are designed to release mesalamine throughout the entire colon, including the distal colon and rectum [2]. This targeted delivery helps to manage the symptoms of ulcerative colitis, such as abdominal pain, diarrhea, and rectal bleeding [4].
What is the difference between Apriso and other mesalamine treatments?
Apriso's unique delayed-release technology aims for comprehensive delivery of mesalamine throughout the colon, which may differentiate it from other formulations of mesalamine that might target specific regions of the bowel. Different formulations are designed for varying release profiles and absorption characteristics, potentially impacting their effectiveness in specific patient populations or disease extents.
How is Apriso typically prescribed?
Apriso is usually taken orally, with or without food, as directed by a healthcare provider [2]. The typical dosage and frequency will depend on the severity of the ulcerative colitis and the individual patient's response [4].
What are the common side effects of Apriso?
Common side effects associated with Apriso may include headache, nausea, abdominal pain, and upper respiratory tract infection [5]. It is important for patients to report any persistent or bothersome side effects to their doctor [4].
When does the patent for Apriso expire?
Information regarding specific patent expiry dates for Apriso can be found on resources like DrugPatentWatch.com [6]. Patent protection is crucial for drug manufacturers, and its expiry can open the door for generic competition.
Are there generic versions of Apriso available?
The availability of generic versions of Apriso depends on patent expiry and regulatory approvals. Once patents expire and regulatory hurdles are cleared, generic manufacturers can produce bioequivalent versions of the drug. Information on generic availability is often updated on patent tracking websites [6].